R.A. Seaton, Gartnavel General Hospital, Glasgow
R.A. Seaton, Gartnavel General Hospital, Glasgow
R.A. Seaton, Gartnavel General Hospital, Glasgow
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Infections treated with OPAT<br />
Infections treated with OPAT<br />
Number of patients<br />
350<br />
300<br />
250<br />
200<br />
150<br />
100<br />
50<br />
Diagnoses for OPAT patients (n=2063)<br />
Other<br />
BJI<br />
SSTI<br />
Number of patients<br />
100<br />
80<br />
60<br />
40<br />
20<br />
Diagnoses for OPAT patients excluding SSTI and BJI<br />
99<br />
89<br />
68<br />
46<br />
34 32<br />
27<br />
13 14<br />
0<br />
2001 2002 2003 2004 2005 2006 2007 2008<br />
Year<br />
0<br />
Bact/Endo<br />
Meninigits<br />
Syphilis<br />
Lyme<br />
LRTI<br />
UTI<br />
TB<br />
Typhoid<br />
Other<br />
LRTI, lower respiratory tract infection; TB, tuberculosis; UTI, urinary tract infection<br />
<strong>Seaton</strong> RA. Unpublished data<br />
<strong>Seaton</strong> RA. Unpublished data<br />
Community treatment pathway for<br />
SSTIs: empiric antibiotic choice<br />
Yes<br />
Anti-MRSA<br />
therapy<br />
Patient at risk for MRSA?<br />
No<br />
Ceftriaxone<br />
±<br />
clindamycin<br />
Patient group direction for SSTIs<br />
• ‘Patient group’: non-lifethreatening<br />
cellulitis amenable for<br />
home care and requiring i.v.<br />
therapy<br />
• Uniform therapeutic management<br />
• Suitable protocol in place<br />
• Exclusions<br />
• Prior physician review<br />
• Indications for specialist review<br />
• Indications for IVOST<br />
• Trained, experienced staff<br />
• Approved by ADTC<br />
IVOST, i.v. antibiotic – oral switch therapy<br />
<strong>Seaton</strong> RA et al. J Antimicrob Chemother 2005;55:764–767
Change language